ATP5PB suppresses colorectal cancer progression by restraining the Galectin-3/PI3K/AKT signaling axis
This study demonstrates that ATP5PB acts as a tumor suppressor in colorectal cancer by interacting with Galectin-3 to inhibit the PI3K/AKT signaling axis, thereby restraining tumor progression and serving as a potential prognostic biomarker and therapeutic target.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
Colorectal cancer is a disease where cells in the lining of the large intestine grow out of control, often spreading to other parts of the body and causing severe illness. To understand how this happens, scientists look at the tiny machines inside our cells that manage energy and the complex chemical signals that tell cells when to grow or stop. One such machine is a protein called ATP synthase, which acts like a battery charger for the cell, generating the energy needed for life. Another key player is a signaling pathway known as PI3K/AKT, which acts as a master switch; when it is turned on too much, it can push cells to multiply rapidly and invade nearby tissues. For years, researchers have known that when these energy machines malfunction or when the growth switches get stuck in the "on" position, cancer can become more aggressive. However, the exact way these two systems talk to each other to drive the disease has remained a mystery.
A team of researchers set out to solve this puzzle by studying a specific part of the cellular energy machine called ATP5PB. They began by looking at vast amounts of genetic data from thousands of patients and then examined tissue samples from 87 people with colorectal cancer. What they found was striking: in healthy colon tissue, the ATP5PB protein is abundant, but in cancerous tissue, it is significantly reduced. The less of this protein a patient had, the more advanced their cancer was, the more likely it was to have spread to lymph nodes, and the shorter their survival time tended to be. This pattern suggested that the loss of ATP5PB was not just a side effect of the disease, but a driver that helped the cancer grow and spread.
To test this idea directly, the scientists worked with colorectal cancer cells in the laboratory. When they artificially removed the remaining ATP5PB from these cells, the cells became much more aggressive, growing faster and moving more easily through barriers, mimicking the behavior of invasive cancer. Conversely, when they forced the cells to make more ATP5PB than usual, the cells slowed down, stopped spreading, and became less likely to invade surrounding tissue. This confirmed that ATP5PB acts as a natural brake on the cancer's ability to become dangerous.
The researchers then dug deeper to understand how this protein works. They discovered that ATP5PB has a direct physical relationship with another protein called Galectin-3. In healthy cells, ATP5PB binds to Galectin-3, keeping it in check. However, when ATP5PB is missing, Galectin-3 is free to activate the PI3K/AKT growth switch. The study showed that without ATP5PB to hold it back, Galectin-3 triggers a cascade of events that turns on the PI3K/AKT pathway, leading to the production of proteins that help cancer cells divide and break through tissue barriers. The researchers visualized this interaction using computer models and laboratory tests, confirming that the two proteins physically touch and that the presence of ATP5PB suppresses the activity of Galectin-3.
To see if these findings held true in a living organism, the team grew tumors in mice using human cancer cells. Mice injected with cells that had high levels of ATP5PB developed much smaller tumors that grew slowly. In contrast, mice injected with cells where ATP5PB was removed developed large, fast-growing tumors. Inside these tumors, the scientists could see that the high-ATP5PB tumors had low levels of the growth-activating proteins, while the low-ATP5PB tumors were flooded with them. This confirmed that the mechanism observed in the lab also operates within a living body.
The study concludes that the loss of ATP5PB is a critical step in allowing colorectal cancer to become aggressive. By failing to restrain Galectin-3, the cell loses control over the PI3K/AKT growth pathway, leading to rapid tumor expansion and spread. While this research does not yet offer a new treatment, it identifies a clear biological mechanism and suggests that restoring ATP5PB activity or blocking the Galectin-3/PI3K/AKT pathway could be a promising strategy for future therapies. The findings also highlight that measuring the levels of ATP5PB in a patient's tumor could help doctors predict how aggressive the cancer might be and how the patient might respond to treatment.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.